Press Releases

Year None2026202520242023

May 22, 2026

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 21, 2026

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 19, 2026

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 07, 2026

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

April 21, 2026

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

March 16, 2026

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 02, 2026

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences